Propylthiouracil embryofetopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:485358Q06.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Propylthiouracil embryofetopathy (also called PTU embryofetopathy or propylthiouracil-induced fetal syndrome) is a rare condition that occurs when a developing baby is exposed to the drug propylthiouracil (PTU) during pregnancy. PTU is a medication used to treat an overactive thyroid gland (hyperthyroidism) in the mother. While PTU can be necessary to protect the mother's health, in some cases it can cross the placenta and affect the baby's development in the womb. The condition mainly affects the development of the urinary tract and kidneys, as well as the face and scalp. Babies born with this condition may have structural problems with the kidneys or the tubes that carry urine, unusual facial features, or scalp abnormalities. The severity can vary widely from one child to another, ranging from mild to more serious structural differences. There is no specific cure for propylthiouracil embryofetopathy. Treatment focuses on managing the individual problems a child is born with, such as surgery to correct urinary tract abnormalities or other supportive care. Early detection through prenatal ultrasound and close follow-up after birth are important parts of care. Families are encouraged to work with a team of specialists to address each child's unique needs.

Also known as:

Key symptoms:

Kidney abnormalities (such as cysts or structural problems)Urinary tract malformationsScalp defects (areas where the skin on the scalp did not form properly)Unusual facial featuresChoanal atresia (blocked nasal passages)Ear abnormalitiesSkin abnormalities on the head or faceProblems with the structure of the ureter (the tube connecting kidney to bladder)

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Propylthiouracil embryofetopathy.

View clinical trials →

No actively recruiting trials found for Propylthiouracil embryofetopathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Propylthiouracil embryofetopathy community →

No specialists are currently listed for Propylthiouracil embryofetopathy.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Propylthiouracil embryofetopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Propylthiouracil embryofetopathyForum →

No community posts yet. Be the first to share your experience with Propylthiouracil embryofetopathy.

Start the conversation →

Latest news about Propylthiouracil embryofetopathy

No recent news articles for Propylthiouracil embryofetopathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which organs are affected in my child, and how serious are the problems?,Does my child need surgery, and if so, when?,How often should my child's kidney function be checked, and what signs of problems should I watch for at home?,Are there any dietary changes or activity restrictions my child needs?,Could this condition affect my child's development or school performance?,Is there any risk of this happening again in a future pregnancy, and what alternatives to PTU exist?,Are there any support groups or resources for families dealing with this condition?

Common questions about Propylthiouracil embryofetopathy

What is Propylthiouracil embryofetopathy?

Propylthiouracil embryofetopathy (also called PTU embryofetopathy or propylthiouracil-induced fetal syndrome) is a rare condition that occurs when a developing baby is exposed to the drug propylthiouracil (PTU) during pregnancy. PTU is a medication used to treat an overactive thyroid gland (hyperthyroidism) in the mother. While PTU can be necessary to protect the mother's health, in some cases it can cross the placenta and affect the baby's development in the womb. The condition mainly affects the development of the urinary tract and kidneys, as well as the face and scalp. Babies born with th

How is Propylthiouracil embryofetopathy inherited?

Propylthiouracil embryofetopathy follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Propylthiouracil embryofetopathy typically begin?

Typical onset of Propylthiouracil embryofetopathy is neonatal. Age of onset can vary across affected individuals.